secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2026-10-07T20:45:15+00:00
Accession:  0001171843-26-006499
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Profound Medical prelim Q3 2026 revenue $9.8-10.0M, up ~85-89% YoY and 45-47% above consensus
--------------------------------------------------------------------------------

- Preliminary Q3 2026 total revenue expected at $9.8M-$10.0M, versus Bloomberg mean analyst consensus of $6.78M as of Oct 7, 2026.
- Revenue up approximately 85% to 89% YoY from $5.3M in Q3 2025, and up 292% to 300% sequentially from $2.5M in Q2 2026.
- Q3 2026 gross margin expected to again exceed 70%, which the company attributes to commercial operations and scale.
- CEO Arun Menawat cites increased commercial activity across the installed base and new customer accounts; figures are preliminary and unaudited.
- Full Q3 2026 results due after market close Thursday, November 5, 2026, with a conference call at 4:30 p.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326006499/0001171843-26-006499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326006499/f8k_100726.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-006499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer